Utility of short-interval follow-up mammography after a benign-concordant stereotactic breast biopsy result.

CONCLUSIONS: This study provides evidence that 6-month follow-up mammography has low clinical utility and unnecessarily increases costs after stereotactic BCBB. A safe and more cost-effective strategy may be resumption of routine mammography at 12 months post-biopsy. PMID: 30172804 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30172804?dopt=Abstract

Source: Breast - August 23, 2018 Category: Cancer & Oncology Authors: Maldonado S, Gandhi N, Ha T, Choi P, Khalkhali I, Kalantari BN, Dauphine C Tags: Breast Source Type: research